AKI-CRRT Debate Preliminary Round

Abstract List

18 Sep 2026 16:00 17:50
Room 103
(C then D)
Heng-Chih Pan Moderator
Mitra Nadim Moderator Hepatorenal Syndrome: Recognition and Management or Disordered Physiology or Iatrogenic FailureManaging Patients With Combined Kidney and Liver FailureHow do I Manage Patients with Acute Liver Failure
Sejoong Kim Moderator Korean Big-Data Experience in AKI and CRRT OutcomesSouth Korea has established a robust nationwide health data infrastructure, enabling large-scale analyses of acute kidney injury (AKI) and continuous renal replacement therapy (CRRT). Leveraging the Health Insurance Review and Assessment Service (HIRA) and National Health Insurance Service (NHIS) databases, Korean researchers have characterized AKI incidence, risk factors, and short- and long-term outcomes across diverse clinical settings. Studies utilizing CRRT data have identified predictors of mortality, renal recovery, and progression to chronic kidney disease. These big-data approaches provide critical real-world evidence, informing clinical practice and guiding future interventional strategies in critically ill patients with AKI.Precision Volume Management in CRRT: Insights from Bioimpedance and BiomarkersOptimal fluid balance is critical in critically ill patients undergoing continuous renal replacement therapy (CRRT), yet accurate volume assessment remains challenging. Bioimpedance analysis (BIA) offers a non-invasive, objective method to quantify fluid overload and guide individualized ultrafiltration targets. Complementing BIA, emerging biomarkers provide dynamic, real-time insights into volume status and end-organ perfusion. Integrating these tools into a precision medicine framework may optimize fluid removal strategies, reduce complications, and improve survival outcomes in CRRT-dependent patients. Prospective validation of this combined approach is warranted.
Yi-Chou Hou Moderator

What will be covered

This showcase features international debate teams discussing contemporary controversies in AKI, AKD, CRRT timing, extracorporeal blood purification, biomarkers, precision nephrology, sepsis-associated AKI, AI, and real-world data.

What participants will learn

• How to evaluate competing evidence and clinical uncertainty.

• How to construct evidence-based arguments and counterarguments.

• How to translate research into bedside decision-making and team-based discussion.

Take-home value

Participants will gain exposure to diverse regional perspectives, critical thinking frameworks, and evidence-based reasoning in controversial AKI-CRRT topics.

Target audience

Young nephrologists, intensivists, physician-scientists, fellows, trainees, and participants interested in academic medicine, clinical research, and international collaboration.

Faculty/speakers

International debate teams from Taiwan, Japan, South Korea, Singapore, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.

Registration requirement / additional fee

Included in congress registration unless otherwise specified. Team participation follows the debate program instructions.
 
Time Session
16:00
16:55
C:Extracorporeal blood purification should be routinely considered in sepsis-associated AKI.
Heng-Chih Pan Moderator
Sejoong Kim Moderator Korean Big-Data Experience in AKI and CRRT OutcomesSouth Korea has established a robust nationwide health data infrastructure, enabling large-scale analyses of acute kidney injury (AKI) and continuous renal replacement therapy (CRRT). Leveraging the Health Insurance Review and Assessment Service (HIRA) and National Health Insurance Service (NHIS) databases, Korean researchers have characterized AKI incidence, risk factors, and short- and long-term outcomes across diverse clinical settings. Studies utilizing CRRT data have identified predictors of mortality, renal recovery, and progression to chronic kidney disease. These big-data approaches provide critical real-world evidence, informing clinical practice and guiding future interventional strategies in critically ill patients with AKI.Precision Volume Management in CRRT: Insights from Bioimpedance and BiomarkersOptimal fluid balance is critical in critically ill patients undergoing continuous renal replacement therapy (CRRT), yet accurate volume assessment remains challenging. Bioimpedance analysis (BIA) offers a non-invasive, objective method to quantify fluid overload and guide individualized ultrafiltration targets. Complementing BIA, emerging biomarkers provide dynamic, real-time insights into volume status and end-organ perfusion. Integrating these tools into a precision medicine framework may optimize fluid removal strategies, reduce complications, and improve survival outcomes in CRRT-dependent patients. Prospective validation of this combined approach is warranted.
16:55
17:50
D:CRRT should be the first-line renal replacement therapy modality for ICU patients with AKI.
Mitra Nadim Moderator Hepatorenal Syndrome: Recognition and Management or Disordered Physiology or Iatrogenic FailureManaging Patients With Combined Kidney and Liver FailureHow do I Manage Patients with Acute Liver Failure
Yi-Chou Hou Moderator